Elanco Animal Health Inc insider trading
Every open-market purchase and sale by Elanco Animal Health Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Elanco Animal Health Inc’s insiders pay?
From March 14, 2019 to August 21, 2026, 16 insiders reported 58 open-market purchases and 1 sale not made under a pre-set plan in Elanco Animal Health Inc. Twelve months after each purchase was reported, the shares were −17.8% against the S&P 500 on average (median −19.3%), over 47 purchases with a full year of prices; 19% beat the index. After sales, the shares moved −27.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 15, 2019 into $7,866 by November 2, 2026, −3.1% a year. It held shares 100% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $30,003 (+15.5% a year), and held throughout $30,003 (+15.5%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Hoover R David | See Remarks | 17 | −17.5% (17) | 24% | 0 | — | March 7, 2025 |
| Harrington Michael J | Director | 7 | −22.7% (6) | 17% | 0 | — | August 13, 2026 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR | 7 | −8.4% (5) | 40% | 0 | — | May 19, 2026 |
| Bilbrey John P | Director | 6 | −26.9% (6) | 0% | 0 | — | November 15, 2022 |
| Kurzius Lawrence Erik | Director | 3 | +100.9% (1) | 100% | 0 | — | August 21, 2026 |
| Modi Rajeev A. | SEE REMARKS | 3 | −36.7% (1) | 0% | 0 | — | May 19, 2026 |
| Anand Kapila K | Director | 2 | −31.6% (2) | 0% | 0 | — | March 3, 2022 |
| Doyle William F | Director | 2 | −38.4% (2) | 0% | 0 | — | May 23, 2024 |
| Garcia Art A | Director | 2 | −23.5% (2) | 0% | 0 | — | May 11, 2021 |
| Herendeen Paul | Director | 2 | −36.7% (1) | 0% | 0 | — | August 10, 2026 |
| Vanhimbergen Robert M | EVP and CFO | 2 | — | — | 0 | — | August 10, 2026 |
| Young Todd S. | See Remarks | 2 | −3.9% (2) | 50% | 0 | — | August 4, 2020 |
| Bayer World Investments B.V. | 10% owner | 0 | — | — | 1 | −27.8% (1) | December 3, 2020 |
| Hicks Michael-Bryant | See Remarks | 1 | −13.7% (1) | 0% | 0 | — | August 26, 2019 |
| Kochevar Deborah Turner | Director | 1 | −18.3% (1) | 0% | 0 | — | September 12, 2019 |
| O'neill Shiv | GC AND CORP SEC | 1 | — | — | 0 | — | August 18, 2026 |
When several insiders traded Elanco Animal Health Inc
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Elanco Animal Health Inc in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 12 buying crowds with six months of prices, it averaged −7.4% against the index. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| May 29, 2026 | 2 buying | −0.9% | not yet | not yet |
| December 31, 2025 | 4 buying | +5.6% | +0.3% | not yet |
| March 31, 2025 | 2 buying | +26.7% | +72.0% | +101.7% |
| August 30, 2024 | 2 buying | −21.8% | −34.0% | −3.7% |
| March 28, 2024 | 3 buying | −15.7% | −22.0% | −45.0% |
| March 31, 2023 | 2 buying | −2.1% | +11.5% | +35.4% |
| September 30, 2022 | 4 buying | −9.1% | −41.5% | −35.3% |
| December 31, 2021 | 2 buying | −3.6% | −8.3% | −38.0% |
| May 28, 2021 | 2 buying | −15.0% | −26.0% | −33.8% |
| August 31, 2020 | 4 buying | +1.2% | −3.9% | −16.3% |
| March 31, 2020 | 4 buying | −24.4% | −10.5% | −24.7% |
| August 30, 2019 | 3 buying | −1.5% | +0.4% | −10.1% |